LY3023414 + pemetrexed + cisplatin

This is a combination regimen consisting of **LY3023414**, a dual PI3K/mTOR kinase inhibitor, **pemetrexed**, an antifolate chemotherapeutic, and **cisplatin**, a platinum-based chemotherapeutic. LY3023414 acts as a small molecule inhibitor targeting both PI3K and mTOR pathways, potentially inhibiting tumor growth and survival signaling and impairing DNA repair mechanisms. Pemetrexed inhibits folate-dependent enzymes essential for DNA and RNA synthesis, while cisplatin forms DNA adducts and crosslinks that cause DNA damage and induce apoptosis. The combination aims to achieve synergistic antitumor effects by targeting complementary oncogenic pathways and mechanisms of chemoresistance. The regimen has been studied in advanced cancers including malignant pleural or peritoneal mesothelioma and NSCLC, with specific trials investigating its efficacy and safety. LY3023414 is developed by Eli Lilly, and Alimta (pemetrexed) is also an Eli Lilly product, while cisplatin is a generic drug produced by multiple manufacturers[5][6][7].

Other names

pemetrexedcisplatin